Your browser doesn't support javascript.
loading
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Stein, Eytan M; DiNardo, Courtney D; Fathi, Amir T; Pollyea, Daniel A; Stone, Richard M; Altman, Jessica K; Roboz, Gail J; Patel, Manish R; Collins, Robert; Flinn, Ian W; Sekeres, Mikkael A; Stein, Anthony S; Kantarjian, Hagop M; Levine, Ross L; Vyas, Paresh; MacBeth, Kyle J; Tosolini, Alessandra; VanOostendorp, Jason; Xu, Qiang; Gupta, Ira; Lila, Thomas; Risueno, Alberto; Yen, Katharine E; Wu, Bin; Attar, Eyal C; Tallman, Martin S; de Botton, Stéphane.
Afiliación
  • Stein EM; Memorial Sloan Kettering Cancer Center, New York, NY.
  • DiNardo CD; Weill Cornell Medical College, New York, NY.
  • Fathi AT; The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Pollyea DA; Massachusetts General Hospital Cancer Center, Boston, MA.
  • Stone RM; Harvard Medical School, Boston, MA.
  • Altman JK; University of Colorado School of Medicine, Aurora, CO.
  • Roboz GJ; Dana-Farber Cancer Institute, Boston, MA.
  • Patel MR; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
  • Collins R; Weill Cornell Medical College, New York, NY.
  • Flinn IW; New York Presbyterian Hospital, New York, NY.
  • Sekeres MA; Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL.
  • Stein AS; University of Texas Southwestern Medical Center, Dallas, TX.
  • Kantarjian HM; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
  • Levine RL; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
  • Vyas P; Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte, CA.
  • MacBeth KJ; The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Tosolini A; Memorial Sloan Kettering Cancer Center, New York, NY.
  • VanOostendorp J; MRC Molecular Haematology Unit and Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals, Oxford, United Kingdom.
  • Xu Q; Celgene Corporation, San Francisco, CA.
  • Gupta I; Celgene Corporation, Summit, NJ.
  • Lila T; Celgene Corporation, Summit, NJ.
  • Risueno A; Celgene Corporation, Summit, NJ.
  • Yen KE; Celgene Corporation, Summit, NJ.
  • Wu B; Celgene Corporation, San Francisco, CA.
  • Attar EC; Celgene Institute for Translational Research Europe, Seville, Spain.
  • Tallman MS; Agios Pharmaceuticals, Inc., Cambridge, MA.
  • de Botton S; Agios Pharmaceuticals, Inc., Cambridge, MA.
Blood ; 133(7): 676-687, 2019 02 14.
Article en En | MEDLINE | ID: mdl-30510081
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Triazinas / Leucemia Mieloide Aguda / Proteínas Mutantes / Aminopiridinas / Isocitrato Deshidrogenasa / Mutación / Recurrencia Local de Neoplasia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Triazinas / Leucemia Mieloide Aguda / Proteínas Mutantes / Aminopiridinas / Isocitrato Deshidrogenasa / Mutación / Recurrencia Local de Neoplasia Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2019 Tipo del documento: Article